Warren Buffet's Berkshire Hathaway Buying Johnson and Johnson, Becton Dickinson

Image via Wikipedia

How many times has Warren Buffett been wrong?  If Buffett is buying Johnson & Johnson, that makes it a buy.  Even with the whole Tylenol fiasco, I think it is oversold.  

Billionaire Warren Buffett's Berkshire Hathaway has been quietly buying shares of Johnson & Johnson, and Becton Dickinson at an astonishing rate.  This endorsement from Omaha, Nebraska's famous billionaire, The Oracle from Omaha, has made these stocks a buy.

Warren Buffett Biography:  The Story of Berkshire Hathaway's Billionaire Chairman

The Snowball:  Warren Buffett and the Business of Life

JNJ at a discount


If you would like more Subscribe To BioPharma Investor for everyday stock news and up to date FDA decisions.  Biopharma Investor

The Essential Biotech Sector Fall Preview

Try WikInvest Here:--;https://www.wikinvest.com/

Stock quotes in this article: DNDN, HGSI, GENZ, ARNA, AMLN, IDIX, PCYC

The Essential Biotech Sector Fall Preview

BOSTON (TheStreet) -- Labor Day is over and Hurricane Earl is out to sea, which means Wall Street is returning to work in earnest for the last three months of the year. To put everyone in the right mindset, I've compiled a "Back to School" guide covering the essential information biotech investors need to profit from what should be a very busy fall season.

New Anti-Clotting Drugs May Have Edge Over Top-Selling Plavix

Image via Wikipedia Health Care, Bristol-Myers Squibb, Sanofi Aventis, Eli Lilly, Astrazeneca

Several recent studies of drugs used to treat and prevent strokes appear to favor AstraZeneca's (AZN) Brilinta and Eli-Lilly's (LLY) Effient over Plavix. Plavix, co-marketed by Bristol-Myers Squibb (BMY) and Sanofi-Aventis (SNY), is the second best-selling drug in the world.

Genzyme Rejects Sanofi Takeover Bid

Image via Wikipedia Latest on Genzyme's Merger with Sanofi-Aventis
By Val Brickates Kennedy and Polya Lesova, MarketWatch

BOSTON (MarketWatch) -- Following weeks of speculation, beleaguered biotech leader Genzyme Corp. on Monday formally rejected a $18.5 billion takeover offer from French pharmaceutical firm Sanofi-Aventis, asserting that the bid substantially undervalues the company.